Abstract | BACKGROUND: METHODS: A randomized controlled trial in HIV-positive youths aged 18-25 years enrolled participants based on cART treatment with TDF (TDF; n=118) or without TDF (no-TDF; n=85), and randomized within those groups to VITD (50,000 IU every 4 weeks) or placebo (PL). We measured FGF23 and VDBP and calculated free 1,25-OH(2)D at baseline and week 12, and compared changes by TDF treatment and VITD randomized group. RESULTS: At baseline, serum FGF23 concentration showed a quadratic relationship with 1,25-OH(2)D most pronounced in the TDF group. At week 12, total and free 1,25-OH(2)D increased in the VITD but not PL groups, independent of TDF use. FGF23 increased in the TDF group receiving VITD, but there was no FGF23 change in the no-TDF group receiving VITD or the PL groups. The adjusted mean change in FGF23 from baseline to week 12 was 7.7 pg/ml in the TDF/VITD group, compared with -1.7 (no-TDF/VITD, P=0.010), -1.3 (TDF/PL, P=0.006) and 1.1 (no-TDF/PL, P=0.035). CONCLUSIONS: These results suggest that TDF-containing cART may alter the FGF23 response to vitamin D supplementation in HIV-infected youths. Clinical trials number: NCT00490412.
|
Authors | Peter L Havens, Rohan Hazra, Charles B Stephensen, Jennifer J Kiser, Patricia M Flynn, Craig M Wilson, Brandy Rutledge, James Bethel, Cynthia G Pan, Leslie R Woodhouse, Marta D Van Loan, Nancy Liu, Jorge Lujan-Zilbermann, Alyne Baker, Bill G Kapogiannis, Catherine M Gordon, Kathleen Mulligan, Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 063 study team |
Journal | Antiviral therapy
(Antivir Ther)
Vol. 19
Issue 6
Pg. 613-8
( 2014)
ISSN: 2040-2058 [Electronic] England |
PMID | 24535626
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-HIV Agents
- FGF23 protein, human
- Organophosphonates
- Reverse Transcriptase Inhibitors
- Cholecalciferol
- Fibroblast Growth Factors
- Fibroblast Growth Factor-23
- Tenofovir
- Adenine
|
Topics |
- Adenine
(analogs & derivatives, therapeutic use)
- Adolescent
- Adult
- Anti-HIV Agents
(therapeutic use)
- Cholecalciferol
(administration & dosage, pharmacokinetics)
- Dietary Supplements
- Female
- Fibroblast Growth Factor-23
- Fibroblast Growth Factors
(blood, metabolism)
- HIV Infections
(drug therapy, metabolism)
- Humans
- Male
- Organophosphonates
(therapeutic use)
- Reverse Transcriptase Inhibitors
(therapeutic use)
- Tenofovir
- Treatment Outcome
- Young Adult
|